PMV Pharmaceuticals (PMVP) Stock Forecast & Price Target

Compare

149 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

PMVP Analyst Ratings

Strong Buy

3 Buy

0 Hold

0 Sell

Based on 3 analysts giving stock ratings to

PMV

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

PMVP Stock 12 Month Forecast

Average Price Target

$5.00

▲(262.32% Upside)

Based on 3 Wall Street analysts offering 12 month price targets for PMV Pharmaceuticals in the last 3 months. The average price target is $5.00 with a high forecast of $5.00 and a low forecast of $5.00. The average price target represents a 262.32% change from the last price of $1.38.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","-1":"-$1","0.75":"$0.75","2.5":"$2.5","4.25":"$4.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$5.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$5.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.75,2.5,4.25,6],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Dec<br/>2024","9":"May<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.49,1.76,2.03,2.3,2.57,2.84,3.1099999999999994,3.38,3.6499999999999995,3.92,4.1899999999999995,4.46,4.7299999999999995,{"y":5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.49,1.76,2.03,2.3,2.57,2.84,3.1099999999999994,3.38,3.6499999999999995,3.92,4.1899999999999995,4.46,4.7299999999999995,{"y":5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.49,1.76,2.03,2.3,2.57,2.84,3.1099999999999994,3.38,3.6499999999999995,3.92,4.1899999999999995,4.46,4.7299999999999995,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.61,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.61,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.86,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.59,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.5,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.63,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.69,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.51,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.37,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.88,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.4,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.49,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$5.00

Average Price Target$5.00

Lowest Price Target$5.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Robert Burns

H.C. Wainwright

Buy

262.32%

Upside

Reiterated

09/19/25

Promising Phase 2 Trial Results and Strategic Plans Support Buy Rating for PMV PharmaceuticalsValuation and Risks. We employ a discounted cash flow (DCF)-based approach to valuing PMV shares. We have employed a 10% probability of approval for rezatapopt in Y220C-mutated P53, KRASwt solid tumors. We utilize an 11% discount rate and 1% terminal growth rate, along with a 32.5% effective tax rate.

Yaron Werber

TD Cowen

―

Buy

―

Reiterated

09/10/25

PMV Pharmaceuticals (PMVP) Gets a Buy from TD CowenTD Cowen analyst Yaron Werber reiterated a Buy rating on PMV Pharmaceuticals Inc. (NASDAQ: PMVP).

Albert Lowe

Craig-Hallum

―

Buy

―

Reiterated

09/10/25

Craig-Hallum Sticks to Its Buy Rating for PMV Pharmaceuticals (PMVP)

Jonathan Miller

Evercore ISI

$18

Buy

1204.35%

Upside

Reiterated

06/30/25

Evercore ISI Keeps Their Buy Rating on PMV Pharmaceuticals (PMVP)

Jeff Jones

Oppenheimer

Buy

334.78%

Upside

Upgraded

11/08/24

PMV Pharmaceuticals upgraded to Outperform from Perform at OppenheimerPMV Pharmaceuticals upgraded to Outperform from Perform at Oppenheimer

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Robert Burns

H.C. Wainwright

Buy

262.32%

Upside

Reiterated

09/19/25

Yaron Werber

TD Cowen

―

Buy

―

Reiterated

09/10/25

PMV Pharmaceuticals (PMVP) Gets a Buy from TD CowenTD Cowen analyst Yaron Werber reiterated a Buy rating on PMV Pharmaceuticals Inc. (NASDAQ: PMVP).

Albert Lowe

Craig-Hallum

―

Buy

―

Reiterated

09/10/25

Craig-Hallum Sticks to Its Buy Rating for PMV Pharmaceuticals (PMVP)

Jonathan Miller

Evercore ISI

$18

Buy

1204.35%

Upside

Reiterated

06/30/25

Evercore ISI Keeps Their Buy Rating on PMV Pharmaceuticals (PMVP)

Jeff Jones

Oppenheimer

Buy

334.78%

Upside

Upgraded

11/08/24

PMV Pharmaceuticals upgraded to Outperform from Perform at OppenheimerPMV Pharmaceuticals upgraded to Outperform from Perform at Oppenheimer

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering PMV Pharmaceuticals

1 Month

xxx

Success Rate

5/9 ratings generated profit

Average Return

+0.72%

reiterated a xxx

rating 24 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 55.56% of your transactions generating a profit, with an average return of +0.72% per trade.

3 Months

xxx

Success Rate

3/9 ratings generated profit

Average Return

+2.30%

reiterated a xxx

rating 24 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 33.33% of your transactions generating a profit, with an average return of +2.30% per trade.

1 Year

Yaron WerberTD Cowen

Success Rate

4/9 ratings generated profit

Average Return

-11.26%

reiterated a buy rating 24 days ago

Copying Yaron Werber's trades and holding each position for 1 Year would result in 44.44% of your transactions generating a profit, with an average return of -11.26% per trade.

2 Years

xxx

Success Rate

3/9 ratings generated profit

Average Return

-18.68%

reiterated a xxx

rating 24 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 33.33% of your transactions generating a profit, with an average return of -18.68% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PMVP Analyst Recommendation Trends

Rating

Mar 25

May 25

Jun 25

Aug 25

Sep 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, PMVP has received 5 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. PMVP average Analyst price target in the past 3 months is 5.00.

Each month's total comprises the sum of three months' worth of ratings.

PMVP Financial Forecast

PMVP Earnings Forecast

Next quarter’s earnings estimate for PMVP is -$0.40 with a range of -$0.43 to -$0.39. The previous quarter’s EPS was -$0.41. PMVP beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year PMVP has Preformed in-line its overall industry.

No data currently available

PMVP Sales Forecast

Next quarter’s sales forecast for PMVP is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. PMVP beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year PMVP has Preformed in-line its overall industry.

PMVP Stock Forecast FAQ

What is PMVP’s average 12-month price target, according to analysts?

Based on analyst ratings, PMV Pharmaceuticals’s 12-month average price target is 5.00.

What is PMVP’s upside potential, based on the analysts’ average price target?

PMV Pharmaceuticals has 262.32% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is PMVP a Buy, Sell or Hold?

PMV Pharmaceuticals has a consensus rating of Strong Buy which is based on 3 buy ratings, 0 hold ratings and 0 sell ratings.

What is PMV Pharmaceuticals’s price target?

The average price target for PMV Pharmaceuticals is 5.00. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $5.00 ,the lowest forecast is $5.00. The average price target represents 262.32% Increase from the current price of $1.38.

What do analysts say about PMV Pharmaceuticals?

PMV Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.

How can I buy shares of PMVP?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

PMV Pharmaceuticals (PMVP) Stock Forecast & Price Target

PMVP Analyst Ratings

PMVP Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering PMV Pharmaceuticals

PMVP Analyst Recommendation Trends

PMVP Financial Forecast

PMVP Earnings Forecast

PMVP Sales Forecast

PMVP Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts